Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
The clients start noticing the skin colour changes within one month and the lasting results last longer from 2 years to 3 years, Especially in those clients who look after well their health and has no disease , health condition or changes in lifestyle
Yadav, H., Lee, J.-H., Lloyd, J., Walter, P., & Rane, S
But since glutathione influences the bodys overall antioxidant status, certain people might feel slight, temporary adverse effects such as nausea or abdominal bloating
